Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer

Journal of Clinical Oncology

Volumn 17, Issue 2, 1999, Pages 485-493

  Blum, Joanne L ^a   Jones, Stephen E ^a   Buzdar, Aman U ^a   LoRusso, Patricia Mucci ^a   Kuter, Irene ^a   Vogel, Charles ^a   Osterwalder, Bruno ^a   Burger, Hans Ulrich ^a   Brown, Cheryl Stoner ^a   Griffin, Tom ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; PACLITAXEL;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; FOOT DISEASE; GASTROINTESTINAL SYMPTOM; HAND DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; STOMATITIS; VOMITING;

EID: 0033050165     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.2.485     Document Type: Article

References (26)

1. Miwa M, Ura M, Nishida M, et al: Design of a novel fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumor by enzymes concentrated in human liver and cancer tissue. Eur J Cancer (in press)
2. Ishikawa T, Sekiguchi F, Fukase Y, et al: Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 58:685-690, 1998
3. Jones A, Harris AL: New developments in angiogenesis: A major mechanism for tumor growth and target for therapy. Cancer J 4:209-217, 1998
4. Ishikawa T, Utoh M, Sawada N, et al: Capecitabine, a new oral fluoropyrimidine carbamate, selectively delivers fluorouracil to tumor tissues in human cancer xenografts. Biochem Pharmacol 55:1091-1097, 1998
5. Cao S, Lu K, Ishisuka H, et al: Antitumor efficacy of capecitabine against fluorouracil-sensitive and -resistant tumors. Proc Am Soc Clin Oncol 16:226a, 1997 (abstr)
6. Twelves C, Budman DR, Creaven PJ, et al: Pharmacokinetics and pharmacodynamics of capecitabine in two phase I studies. Proc Am Soc Clin Oncol 15:479, 1996 (abstr)
7. Schuller J, Cassady J, Reigner BG, et al: Tumor selectivity of Xeloda in colorectal cancer patients. Proc Am Soc Clin Oncol 16:227a, 1997 (abstr)
8. MacKean, MJ, Planting AS, Twelves C, et al: Phase I and pharmacologic study of intermittent twice daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol 16:2977-2985, 1998
9. Budman DR, Meropol NJ, Reigner B, et al: Preliminary studies of a novel fluoropyrimidine carbamate: Capecitabine. J Clin Oncol 16:1795-1802, 1998
10. Dickson RB, Lippman ME: Cancer of the breast, in Devita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practices of Oncology (ed 5). Philadelphia, PA, Lippincott-Raven, 1997, pp 1541-1557
11. Valero V, Burris HA III, Jones SE, et al: Multicenter pilot study of Taxotere in Taxol-resistant metastatic breast cancer. Proc Am Soc Clin Oncol 15:107, 1996 (abstr)
12. Fazeny B, Zifko U, Meryn S, et al: Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel: A phase II study. Cancer Chemother Pharmacol 39:150-156, 1996
13. Livingston RB, Ellis GK, Gralow JR, et al: Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 15:1395-1400, 1997
14. Henderson IC: Principles in the management of metastatic disease: Chemotherapy for metastatic disease, in Harris JR, Hellman S, Henderson IC, et al (eds): Breast Diseases. Philadelphia, PA, Lippincott, 1991, pp 604-665
15. Abrams JS, Vena DA, Baltz J, et al: Paclitaxel activity in heavily pretreated breast cancer: A National Cancer Institute Treatment Referral Center trial. J Clin Oncol 13:2056-2065, 1995
16. Valero V, Holmes FA, Walters RS, et al: Phase II trial of docetaxel: A new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 13:2886-2894, 1995
17. Howell A, Mackintosh J, Jones M, et al: The definition of the "no change" category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. Eur J Cancer Clin Oncol 24:1567-1572, 1988
18. Anderson JR, Cain KC, Gelber RD, et al: Analysis and interpretation of the comparison of survival by treatment outcome variables in cancer clinical trials. Cancer Treatment Rep 69:1139-1144, 1985
19. Anderson JR, Cain KS, Gelber RD: Analysis of survival by tumor response. J Clin Oncol 1:710-719, 1983
20. Seidman AD, Portenoy R, Yao TJ, et al: Quality of life in phase II trials: A study of methodology and predictive value in patients with advanced breast cancer treated with paclitaxel plus granulocyte colony-stimulating factor. J Natl Cancer Inst 87:1316-1322, 1995
21. Burris HA, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: A randomized trial. J Clin Oncol 15:2403-2413, 1997
22. Fishman B, Pasdernak S, Wallenstein SC, et al: The Memorial Pain Assessment Card: A valid instrument for the evaluation of cancer pain. Cancer 60:1151-1158, 1987
23. Schag CC, Heinrich RL, Ganz PA: Karnofsky performance status revisited: Reliability, validity, and guidelines. J Clin Oncol 2:187-193, 1984
24. Turner JA, Deyo RA, Loesor JD, et al: The importance of placebo effects in pain treatment and research. JAMA 271:1609-1614, 1994
25. Meropol NJ, Rustum YM, Petrelli NJ, et al: A phase I and pharmacokinetic study of oral uracil, ftorafur and leucovorin in patients with advanced cancer. Cancer Chemother Pharmacol 37:581-586, 1996
26. Liu G, Franssen E, Fitch MI, et al: Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15:110-115, 1997